Development of a two-component recombinant vaccine for COVID-19
This novel two-component recombinant vaccine exhibits high immunogenicity and offers a potential booster strategy for COVID-19 vaccine development.
Authors
- Qiao-Min Li
- Yisheng Sun
- Yong Xia (ORCID: https://orcid.org/0000-0002-8611-6455)
- Zhan Zhou (ORCID: https://orcid.org/0000-0002-2730-5483)
- Zhen Wang (ORCID: https://orcid.org/0000-0002-6401-4968)
- Yuanyuan Luo (ORCID: https://orcid.org/0000-0002-3826-3637)
- Beibei Wu (ORCID: https://orcid.org/0000-0002-4788-0469)
- Han-Ping Zhu
- Hang-Jing Lu
- Ping-Ping Yao
- Fang Xu (ORCID: https://orcid.org/0009-0001-3534-815X)
Institutions
- Zhejiang Lab (CN)
- Zhejiang Center for Disease Control and Prevention (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-20
- DOI
- https://doi.org/10.3389/fimmu.2024.1514226
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Basic Public Welfare Research Program of Zhejiang Province